Article (Scientific journals)
Development of new drugs for an old target — the penicillin binding proteins.
Zervosen, Astrid; Sauvage, Eric; Frère, Jean-Marie et al.
2012In Molecules, 17 (11), p. 12478-505
Peer Reviewed verified by ORBi
 

Files


Full Text
molecules-17-12478.pdf
Publisher postprint (460.86 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
non-beta-lactam; Penicillin Binding Protein
Abstract :
[en] The widespread use of β-lactam antibiotics has led to the worldwide appearance of drug-resistant strains. Bacteria have developed resistance to β-lactams by two main mechanisms: the production of β-lactamases, sometimes accompanied by a decrease of outer membrane permeability, and the production of low-affinity, drug resistant Penicillin Binding Proteins (PBPs). PBPs remain attractive targets for developing new antibiotic agents because they catalyse the last steps of the biosynthesis of peptidoglycan, which is unique to bacteria, and lies outside the cytoplasmic membrane. Here we summarize the “current state of the art” of non-β-lactam inhibitors of PBPs, which have being developed in an attempt to counter the emergence of β-lactam resistance. These molecules are not susceptible to hydrolysis by β-lactamases and thus present a real alternative to β-lactams. We present transition state analogs such as boronic acids, which can covalently bind to the active serine residue in the catalytic site. Molecules containing ring structures different from the β-lactam-ring like lactivicin are able to acylate the active serine residue. High throughput screening methods, in combination with virtual screening methods and structure based design, have allowed the development of new molecules. Some of these novel inhibitors are active against major pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and thus open avenues new for the discovery of novel antibiotics.
Research center :
GIGA CRC (Cyclotron Research Center) In vivo Imaging-Aging & Memory - ULiège
CIP - Centre d'Ingénierie des Protéines - ULiège
Disciplines :
Immunology & infectious disease
Biochemistry, biophysics & molecular biology
Microbiology
Author, co-author :
Zervosen, Astrid ;  Université de Liège - ULiège > Centre de recherches du cyclotron
Sauvage, Eric ;  Université de Liège - ULiège > Centre d'ingénierie des protéines
Frère, Jean-Marie ;  Université de Liège - ULiège > Centre d'ingénierie des protéines
Charlier, Paulette ;  Université de Liège - ULiège > Département des sciences de la vie > Cristallographie des macromolécules biologiques
Luxen, André ;  Université de Liège - ULiège > Département de chimie (sciences) > Chimie organique de synthèse
Language :
English
Title :
Development of new drugs for an old target — the penicillin binding proteins.
Publication date :
2012
Journal title :
Molecules
eISSN :
1420-3049
Publisher :
Multidisciplinary Digital Publishing Institute (MDPI), Switzerland
Volume :
17
Issue :
11
Pages :
12478-505
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 15 November 2012

Statistics


Number of views
122 (10 by ULiège)
Number of downloads
4 (4 by ULiège)

Scopus citations®
 
81
Scopus citations®
without self-citations
77
OpenCitations
 
83

Bibliography


Similar publications



Contact ORBi